Iranian consensus on use of vitamin D in patients with multiple sclerosis

Jahromi, S. R. and Sahraian, M. A. and Togha, M. and Sedighi, B. and Shayegannejad, V. and Nickseresht, A. and Nafissi, S. and Mohebbi, N. and Majdinasab, N. and Foroughipour, M. and Etemadifar, M. and Moghadam, N. B. and Ayramlou, H. and Ashtari, F. and Alaie, S. (2016) Iranian consensus on use of vitamin D in patients with multiple sclerosis. BMC Neurology, 16 (1).

[img] Text

Download (523kB)


Background: Accumulating evidences from experimental, epidemiologic and clinical studies support the potential linkage between poor vitamin D status and the risk of developing Multiple Sclerosis (MS), as well as, an adverse disease course. However, the results of the trials on the clinical outcomes of vitamin D supplementation in MS patients are less consistent which brought many discrepancies in routine practice. In this article we presented a summary of a symposium on vitamin D and MS. In this symposium we aim to review the current data about the relationship between vitamin D and MS, and suggest management guides for practicing neurologists. Discussion: Generally, supplementation seems to be reasonable for all MS and clinically isolated syndrome (Rinaldi et al., Toxins 7:129-37, 2015) patients with serum 25(OH)D level below 40ng/ml. In patients with vitamin D insufficiency or deficiency, a large replacing dose (e.g. 50,000IU capsules of D per week for 8-12 week) is recommended. Panel also suggested: the checking of the serum vitamin D, and calcium level, as well as, patients' compliance after the initial phase; a maintenance treatment of 1500-2000IU daily or equivalent intermittent (weekly, biweekly or monthly) Dose, considering the patient's compliance; routine check of serum vitamin D level at least two times a year especially at the beginning of spring and autumn; Serum vitamin D evaluation for first degree relatives of MS patients at high risk age and supplementation in case of insufficiency (25(OH)D less than 40 ng/ml); correction of vitamin D deficiency and insufficiency before pregnancy, as well as, a daily dose of 1500-2000IU or equivalent biweekly intake in 2nd and 3rd trimesters; stopping supplementation if 25(OH)D serum level exceeds 100ng/ml. Summary: Although the results of high power studies are not available, correcting vitamin D status seems plausible in all MS and CIS patients. Maintaining the serum 25(OH)D level between 40 and 100 ng/ml is not known to exert adverse effect. More ever, it might be associated with lower disease activity. © 2016 Jahromi et al.

Item Type: Article
Additional Information: Cited By :4 Export Date: 16 February 2020 CODEN: BNMEC Correspondence Address: Sahraian, M.A.; MS Research Center, Neuroscience Institute, Tehran University of Medical SciencesIran; email:
Uncontrolled Keywords: Assessment Etiology Multiple sclerosis Pathogenesis Treatment Vitamin D 25 hydroxyvitamin D calcium interleukin 17 Article calcium blood level clinical effectiveness consensus cytokine production disease association disease predisposition human Iranian people nutritional status outcome assessment patient compliance physical activity pregnancy risk assessment risk factor vitamin blood level vitamin D deficiency vitamin supplementation blood complication female Iran Humans
Subjects: WE Musculoskeletal system
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib4 lib4
Date Deposited: 02 Mar 2020 05:12
Last Modified: 02 Mar 2020 05:12

Actions (login required)

View Item View Item